Early trial results from the AURORAS-1 and JYP0015M101 studies show that ERAS-0015, a new pan-RAS “molecular glue,” may be highly effective in treating solid tumors with KRAS G12X mutations, including lung and pancreatic cancers.
In patients with non-small cell lung cancer, the drug achieved response rates of 62% in those receiving second-line or later treatment, rising to 75% in patients previously treated with chemotherapy and immunotherapy. In pancreatic cancer, the response rate reached 40% in second-line patients. Many responses appeared durable, with most patients still on treatment at the time of analysis in early 2026.
The drug was well tolerated, with mostly mild side effects and no treatment discontinuations due to toxicity. ERAS-0015 works by targeting multiple RAS forms, potentially overcoming resistance seen with other therapies. Larger studies are ongoing, with more data expected in 2027.